Corporate Events

Asanuma Corporation announced that Seiya Kinoshita, Outside Director, will resign effective September 30, 2026. The resignation is due to personal reasons.

The company closed its plan on August 25, 2026.

From August 6, 2026 to August 25, 2026, the company has repurchased 1,083,000 shares, representing 1.34% for ¥999.91 million. With this, the company has completed the repurchase of 1,083,000 shares, representing 1.34% for ¥999.91 million under the buyback announced on August 6, 2026.

Asanuma Corporation, Q1 2027 Earnings Call, Aug 25, 2026

Asanuma Corporation provided consolidated earnings guidance for the full year ending March 31, 2027. For the year, on consolidated basis, the company expected net sales of JPY 175,500 million; Operating profit of JPY 7,780 million; Profit attributable to owners of parent of JPY 5,180 million; and Earnings per share of JPY 64.22.

Asanuma Corporation reported earnings results for the first quarter ended June 30, 2026. For the first quarter, the company reported sales was JPY 37,368 million compared to JPY 42,706 million a year ago. Revenue was JPY 37,369 million compared to JPY 42,707 million a year ago. Net income was JPY 1,138 million compared to JPY 712 million a year ago. Basic earnings per share from continuing operations was JPY 14.1 compared to JPY 8.84 a year ago.

The Board of Directors of Asanuma Corporation has authorized a buyback plan on August 7, 2026.

Asanuma Corporation, Board Meeting, Aug 06, 2026. Agenda: To consider acquisition of treasury stock pursuant to Article 156 of the Companies Act, as applied mutatis mutandis pursuant to Article 165, Paragraph 3 of the same Act, and pursuant to Article 178 of the Companies Act, resolved matters relating to the cancellation of treasury stock.

Asanuma Corporation, ¥ 17.0, Cash Dividend, Sep-29-2026

From July 1, 2026 to July 2, 2026, the company has repurchased 300,000 shares, representing 0.37% for ¥258.57 million. With this, the company has completed the repurchase of 300,000 shares, representing 0.37% for ¥258.57 million under the buyback announced on June 25, 2026.

The company closed its plan on July 2, 2026.

From June 25, 2026 to June 30, 2026, the company has repurchased 0 shares, representing 0% for ¥0 million. With this, the company has completed the repurchase of 0 shares, representing 0% for ¥0 million under the buyback announced on June 25, 2026.

Asanuma Corporation, Board Meeting, Jun 25, 2026. Agenda: To consider and approve Regarding Decision on Matters Relating to Treasury Stock Acquisition.

The Board of Directors of Asanuma Corporation has authorized a buyback plan on June 25, 2026.

Asanuma Corporation (TSE:1852) announces a share repurchase program. Under the program, the company will repurchase up to 300,000 shares, representing 0.37% of its issued share capital (excluding treasury stock), for a total purchase price of ¥270 million. The purpose of the program is providing incentives for the sustainable improvement of corporate value and further promoting value sharing with shareholders. The program will be valid till July 31, 2026. As of March 31, 2026, the company had 80,726,816 issued shares (excluding treasury stock) and 59,474 treasury shares.

The U.S. Food and Drug Administration (FDA) has issued Warning Letter No. 721136 to Asanuma Corporation - Sagamihara Factory on CGMP. The warning letter was issued through the Center for Drug Evaluation and Research (CDER). The facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records company submitted in response to the August 25, 2025, request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for the facility, Asanuma Corporation - Sagamihara Factory, FEI 3010960168, at 1 Chome 14-41, Nishihashimoto, Midori, Sagamihara, Kanagawa, as well as subsequent correspondence. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211). Because the methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in the response to the 704(a)(4) request do not conform to CGMP, the drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)). The firm manufactures (b)(4), an OTC (b)(4) drug product labeled to contain the active drug ingredients (b)(4). This drug product is also labeled and formulated to contain the inactive ingredient talc. Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth. Asbestos is a potential contaminant in talc and is a known human carcinogen when inhaled.[1,2] Your (b)(4) drug product, (b)(4), is considered a higher-risk drug as it pertains to patient safety regarding asbestos contamination of talc due to the risk of inadvertent inhalation. Company have not demonstrated that company appropriately tested incoming talc drug components used in the manufacture of the (b)(4) drug products for identity, purity, strength, and quality. In response to the 704(a)(4) request, company indicate that company did not perform testing for asbestos in talc, and the review found that company do not conduct identity testing on talc prior to use in the manufacture of the drug products. Company also failed to provide records indicating that company established the reliability of the supplier's analyses through appropriate validation of the supplier's test results. Although 21 CFR 211.84(d)(2) provides for some reliance on a certificate of analysis (COA) from the supplier of the component, such reliance is permissible only if the drug product manufacturer establishes the reliability of the supplier's test results through appropriate validation of the test results at appropriate intervals. Without adequate testing, company lack scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of the drug products. As a manufacturer, company have a responsibility to sample, test, and examine, as appropriate, drug components before use in production to ensure acceptable specifications for identity, strength, quality, and purity are met. Because company have not performed appropriate testing that detects asbestos in the talc components, among other things, company failed to assure the acceptability of these drug components for use in manufacture of the drug products.

Asanuma Corporation announced that they will report Q1, 2027 results on Aug 06, 2026

Asanuma Corporation (TSE:1852) signed a letter of intent to acquire 80% stake in T3 International Pte. Ltd. from Choy Wai Kong and Tan Woon Szu for SGD 8 million on May 19, 2026. A cash consideration of SGD 8 million will be paid by Asanuma Corporation. As part of consideration, SGD 8 million is paid towards common equity of T3 International Pte. Ltd. In the second transfer vendors will sell Additional 100,000 shares representing 20% Stake, Subject to change based on business performance. The second Transfered is planned to be done in September 2029. The expected completion of the transaction is in mid-June 2026.

Asanuma Corporation provided cash dividend guidance of JPY 28.00 per share for the fiscal year ending March 31, 2027 as compared to JPY 29.00 per share a year ago.

Asanuma Corporation proposed cash dividend of JPY 29.00 per share for the fiscal year ended March 31, 2026 as compared to JPY 26.00 per share a year ago. Scheduled date of annual general meeting of shareholders: June 25, 2026; Scheduled date to commence dividend payments: June 26, 2026. For the second quarter of fiscal year ending March 31, 2027, the company expected cash dividend of JPY 17.00 per share as compared to JPY 16.00 per share a year ago.

Asanuma Corporation provided consolidated and non-consolidated earnings guidance for the full year ending March 31, 2027. For the year, on consolidated basis, the company expected net sales of JPY 175,500 million; Operating profit of JPY 7,780 million; Profit attributable to owners of parent of JPY 5,180 million; and Earnings per share of JPY 64.22. For the year, on non-consolidated basis, the company expected net sales of JPY 162,900 million; Operating profit of JPY 6,960 million; Profit of JPY 5,340 million; and Earnings per share of JPY 66.20.

Asanuma Corporation, Board Meeting, May 19, 2026. Agenda: To consider and approve to resolved to refer a matter regarding the dividend of surplus.

Asanuma Corporation, Annual General Meeting, Jun 25, 2026.

Asanuma Corporation announced that they will report fiscal year 2026 results on May 13, 2026

Asanuma Corporation, 2026 Earnings Call, May 25, 2026

ASANUMA CORPORATION announced that, at a Board of Directors’ meeting held March 31, 2026, it resolved to close two local subsidiaries in the Kingdom of Thailand that were established in 2021. The date of the suspension of business is April 30, 2026. The Company expects it will take about one to two years to complete the closure of these local subsidiaries due to liquidation procedures. Reason for Closure: These two local subsidiaries have been carrying out work to reinforce civil engineering and building structures using carbon fiber in the Kingdom of Thailand. However, the Company has decided to close these two local subsidiaries as part of efforts to streamline its operations. The Company expects the impact from the closure of these two local subsidiaries on consolidated financial results to be minor. Asanuma Corporation announced the closure of its two local subsidiaries, Thai Asanuma Holdings Co. Ltd. and Thai Asanuma Construction Co. Ltd. Thai Asanuma Holdings Co. Ltd. was located at 2034/70 15th Floor, Italthai Tower, New Petchburi Road, Bangkapi, Huaikwang, Bangkok 10310, with a business description of holding shares in operating companies and sales of construction materials, and was established in June 2021 with a capital of THB 4,000,000. Thai Asanuma Construction Co. Ltd. was also located at 2034/70 15th Floor, Italthai Tower, New Petchburi Road, Bangkapi, Huaikwang, Bangkok 10310, with a business description of general construction, and repair and reinforcement of building structures, and was established in July 2021 with a capital of THB 5,000,000.

Asanuma Corporation, Board Meeting, Mar 31, 2026. Agenda: To resolve to close two local subsidiaries in the Kingdom of Thailand that were established in 2021.

Asanuma Corporation announced that at the Board of Directors meeting held on March 19, 2026, it was resolved to revise the final dividend forecast for the fiscal year ending March 31, 2026. For the year-end, the company expects to pay dividend of JPY 29.00 per share against previous guidance of JPY 27.50 per share. 2. Reason for the Revision of Dividend Forecast: The Company considers returning profits to shareholders to be one of its most important management priorities. To this end, the basic policy is to develop new technologies necessary for future business expansion, while striving to maintain and strengthen the company's competitiveness and to distribute profits based on business performance. In addition to the above policy, considering recent business performance trends and the shareholder return plan that targets a consolidated dividend ratio of at least 70% in the three-year medium term plan (fiscal year 2024-2026), the Company will raise the year-end dividend forecast to JPY 29 per share, an increase of JPY 1.50 per share from the previous forecast. As a result, the annual dividend forecast for the fiscal year ending March 31, 2026 will be JPY 45 per share, representing an increase of JPY 3.50 per share from the initial annual dividend forecast disclosed on May 14, 2025, and an increase of JPY 4 per share from the actual annual dividend for the fiscal year ended March 31, 2025. The final dividend will be officially decided by a resolution at the 91th Annual General Meeting of shareholders, which will be held in late June 2026.

Asanuma Corporation, Board Meeting, Mar 19, 2026. Agenda: To consider the final dividend forecast for the fiscal year ending March 31, 2026.

ASANUMA CORPORATION resolved to make changes in Executive Officers in the meeting of the Board of Directors held today. Shunji Nakanishi was appointed as Executive Officer, General Manager in charge of Nagoya Branch, effective April 1, 2026. Previously, he served as General Manager in charge of Building Construction Division, Nagoya Branch. Masatoshi Yano was appointed as Executive Officer, Deputy General Manager in charge of Building Construction Headquarters, General Manager in charge of Architectural Technology Division, Building Construction Headquarters, effective April 1, 2026. Previously, he served as General Manager in charge of Architectural Technology Division, Building Construction Headquarters. Shogo Uo was appointed as Executive Officer, Deputy General Manager in charge of Civil Construction Headquarters (responsible for Western Japan), effective April 1, 2026. Previously, he served as General Manager in charge of Tokyo Civil Engineering Division, Civil Construction Headquarters. Fumitaka Okamoto was appointed as Executive Officer, Deputy General Manager in charge of Tokyo Main Office (responsible for Building Construction), Deputy General Manager in charge of Safety, Quality and Environment Headquarters, effective April 1, 2026. Previously, he served as Deputy General Manager in charge of Tokyo Main Office (responsible for Building Construction), Deputy General Manager in charge of Safety, Quality and Environment Headquarters. Naoki Watanabe was appointed as Executive Officer, Deputy General Manager in charge of Tokyo Main Office (responsible for Building Construction Marketing & Sales), effective April 1, 2026. Previously, he served as Deputy General Manager in charge of Tokyo Main Office (responsible for Building Construction Marketing & Sales). Seiichiro Ishihara retired as Managing Executive Officer, Deputy General Manager in charge of Corporate Strategy and Planning Headquarters, General Manager in charge of Strategic Business Promotion Division, effective March 31, 2026, and is scheduled to assume office as Counselor effective April 1, 2026. Koichi Miyake retired as Executive Officer, Deputy General Manager in charge of Building Construction Headquarters (responsible for ReQuality), General Manager in charge of GOOD CYCLE BUILDING Marketing & Sales Promotion Division, Building Construction Headquarters, effective March 31, 2026, and is scheduled to assume office as Counselor effective April 1, 2026. Koji Ouchi retired as Executive Officer, Deputy General Manager in charge of Civil Construction Headquarters (responsible for Eastern Japan), effective March 31, 2026, and is scheduled to assume office as Counselor effective April 1, 2026. Takeshi Fuchida retired as Executive Officer, General Manager in charge of Nagoya Branch, effective March 31, 2026, and is scheduled to assume office as Counselor effective April 1, 2026. Akihiro Toyota changed responsibilities to Senior Managing Executive Officer, General Manager in charge of Corporate Strategy and Planning Headquarters, General Manager in charge of Strategic Business Promotion Division, effective April 1, 2026. Takeomi Asai changed responsibilities to Executive Officer, Deputy General Manager in charge of Safety, Quality and Environment Headquarters, effective April 1, 2026. Noboru Harada changed responsibilities to Executive Officer, Deputy General Manager in charge of Building Construction Headquarters, General Manager in charge of GOOD CYCLE BUILDING Marketing & Sales Promotion Division, Building Construction Headquarters, effective April 1, 2026.

Asanuma Corporation revised dividend guidance for the year ending March 31, 2026. for the year end, the company expects dividend of JPY 27.50 per share against JPY 26.00 per share a year ago.

Asanuma Corporation revised consolidated earnings guidance for the full year ending March 31, 2026. For the year ending March 31, 2026, the company expects consolidated net sales of JPY 174,600 Million, operating profit of JPY 7,550 million, profit attributable to owners of parent of JPY 5,000 million and earnings per share of JPY 62.00.

Asanuma Corporation reported earnings results for the nine months ended December 31, 2025. For the nine months, the company reported sales was JPY 128,157 million compared to JPY 115,299 million a year ago. Revenue was JPY 128,158 million compared to JPY 115,300 million a year ago. Net income was JPY 4,867 million compared to JPY 3,511 million a year ago. Basic earnings per share from continuing operations was JPY 60.36 compared to JPY 43.56 a year ago.

Asanuma Corporation, Board Meeting, Feb 10, 2026. Agenda: To consider the Notice Concerning Revision (Increase) of Dividend Forecast.

Asanuma Corporation, Q3 2026 Earnings Call, Feb 26, 2026

Asanuma Corporation expected to report Fiscal Year 2026 results on May 14, 2026. This event was calculated by S&P Global (Created on February 11, 2026).

Asanuma Corporation announced that they will report Q3, 2026 results on Feb 10, 2026

Asanuma Corporation announced dividend for the second quarter end (interim) of fiscal year ending March 31, 2026. For the second quarter end, the company announced dividend of JPY 16.00 per share compared to JPY 15.00 per share a year ago. Scheduled date to commence dividend payments: December 2, 2025. Record date is September 30, 2025.

Asanuma Corporation, ¥ 29.0, Cash Dividend, Mar-30-2026

Asanuma Corporation expected to report Q3 2026 results on February 6, 2026. This event was calculated by S&P Global (Created on January 11, 2026).

Asanuma Corporation, Board Meeting, Nov 11, 2025. Agenda: To consider the dividend of surplus with a record date of September 30, 2025; and to consider the other matters.

Asanuma Corporation, Q2 2026 Earnings Call, Nov 17, 2025